Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.54 |
| ▸ | FLT1 | P17948 | 14/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7667136 | 0.89 | EGFR (0.56) | EGFRFLT1KDRSYK | |
| SCHEMBL6309229 | 0.87 | EGFR (0.55) | EGFRFLT1KDRSYKPYGL | |
| SCHEMBL7670017 | 0.87 | EGFR (0.56) | EGFRFLT1KDRSYK | |
| SCHEMBL7667846 | 0.85 | EGFR (0.55) | EGFRFLT1KDRSYK | |
| SCHEMBL7665614 | 0.83 | EGFR (0.55) | EGFRFLT1KDRSYK | |
| SCHEMBL7662970 | 0.83 | EGFR (0.56) | EGFRFLT1KDR | |
| SCHEMBL7671129 | 0.83 | EGFR (0.56) | EGFRFLT1KDRSYK | |
| SCHEMBL7669869 | 0.82 | EGFR (0.52) | EGFRFLT1KDRSYK | |
| SCHEMBL6625387 | 0.82 | EGFR (0.53) | EGFRFLT1KDRSYKPYGL | |
| SCHEMBL7673153 | 0.82 | EGFR (0.55) | EGFRFLT1KDRSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | LUZZIO MICHAEL JOSEPH (US) | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004511-A1 | Thiophene derivatives useful as anticancer agents | CCNA1, CCNE1, TP53 | EGFR 698/4885FLT1 468/4885KDR 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.